#USA #San Diego #Life Sciences #financial intelligence #Condor Software

Condor Software Secures $24 Million Series A Funding

In a significant development within the biopharmaceutical landscape, Condor Software announced the successful closure of a $24 million Series A funding round. This funding was spearheaded by notable global software investor Insight Partners, alongside contributions from Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, and Prebys Ventures, raising the total financial backing for Condor to an impressive $36 million.

Addressing a Critical Need in Life Sciences

With approximately $300 billion annually spent on research and development (R&D) by pharmaceutical companies, the industry is in desperate need for innovative solutions to streamline financial processes. Current reliance on manual spreadsheets and disconnected financial systems often leads to most promising clinical trials being halted or abandoned due to lack of clarity on spending and budget performance.

Jennifer Kyle, the Founder and CEO of Condor Software, is well aware of these challenges. Having initially built the financial workflows utilized across the pharmaceutical sector for managing clinical trial finances, her decision to establish Condor was rooted in a vision to provide a robust Financial Intelligence Platform that gathers and integrates clinical, operational, and financial data.

Key Features of the Platform

Condor's platform is distinguished by its three core modules:

• - Connect: This module integrates clinical and financial data within an enterprise ecosystem, establishing a cohesive source of truth.
• - Compass: This element forecasts costs, models various scenarios, and highlights potential risks as projects develop.
• - Copilot: This feature automates vital accounting tasks, including accruals, reconciliations, and monthly closing processes.

The platform's innovative approach utilizes proprietary clinical and financial ontologies, allowing it to map pivotal relationships between trial protocols, activities at various sites, vendor contracts, and financial regulations. Years of collaboration with Big 4 accounting firms have resulted in a system that is embedded within audit-grade workflows, ensuring reliability.

Impressive Outcomes and Customer Trust

Handling over $19 billion in R&D expenditures, Condor Software has earned the trust of finance, accounting, and clinical operations teams within leading biopharma organizations, including Acadia Pharmaceuticals, Alumis Therapeutics, BridgeBio Pharma, and Madrigal Pharmaceuticals. Notably, customers have reported over 90% accuracy in forecasting, a remarkable 70% reduction in month-end closing time, and an average savings of 30% on budgets through the utilization of the platform.

Future Directions with Series A Funding

The funds raised in this latest round will play a vital role in expediting the expansion of Condor's platform. The company plans to enhance its capabilities specifically tailored for leading pharmaceutical firms while also scaling its engineering, product development, design, sales, and customer success teams. The current workforce comprises industry veterans from organizations such as Medidata, BenchSci, Oracle, Benchling, Salesforce Life Sciences, and Ernst & Young.

Supporting Statements from Industry Leaders

Jennifer Kyle insightfully remarked, "Therapies save lives, yet financial visibility remains a challenge. With my vision, Condor seeks to eliminate this barrier, empowering life sciences teams to make informed financial decisions that can ultimately save groundbreaking therapies from being sidelined."

Further support came from Vince Barella, Director of Research and Development Accounting at Alumis Therapeutics, who noted that Condor's automation of traditionally manual tasks is anticipated to improve operational efficiency by 30-40%.

Additionally, Insight Partners' Vice President, Alexander Leibowitz, emphasized the foundational role of Condor's financial intelligence in clinical trial management, heralding it as a transformative addition to the life sciences sector.

Overall, Condor Software’s latest funding round is set to propel the company's mission of providing clear financial insight amidst the evolving landscape of life sciences. With a commitment to innovative technology and the backing of esteemed investors, Condor is positioned to make significant strides in reshaping the financial intelligence domain within the biopharmaceutical industry.